Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Azacitidine in Recurrent, Resectable Osteosarcoma
NCT03628209Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and azacitidine in osteosarcoma (OS), sponsored by Moffitt Cancer Center. Primary endpoints: Recommended Phase II Dose at 60 days and Rate of Continued Complete Remission. Started Oct 2019; status: active, not recruiting.
02
Drugs
nivolumabazacitidine
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03628209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03628209.